Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.70 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.70 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801499 | 1.00 | P2RY10 (0.70) | P2RY10GPR34GPR174 | |
| SCHEMBL1800150 | 0.94 | P2RY10 (0.73) | P2RY10GPR34GPR174 | |
| SCHEMBL15928070 | 0.87 | P2RY10 (0.72) | P2RY10GPR34GPR174 | |
| SCHEMBL15927983 | 0.87 | P2RY10 (0.72) | P2RY10GPR34GPR174 | |
| SCHEMBL19941696 | 0.87 | P2RY10 (0.72) | P2RY10GPR34GPR174 | |
| Dexfosfoserine SCHEMBL28465640 | 0.85 | ENPP2 (0.70) | P2RY10GPR34GPR174 | |
| Dexfosfoserine SCHEMBL28767573 | 0.85 | ENPP2 (0.70) | P2RY10GPR34GPR174 | |
| 1,2-Dipalmitin SCHEMBL21382909 | 0.85 | ENPP2 (0.70) | P2RY10GPR34GPR174 | |
| Phosphatidyl Serine SCHEMBL24802704 | 0.85 | P2RY10 (0.75) | P2RY10GPR34GPR174 | |
| SCHEMBL22531350 | 0.85 | P2RY10 (0.75) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202040-B2 | Method for screening compounds which change the binding properties of a protein with a ligand | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-10 | — | — | US | claimed |
| US-7951548-B2 | IL-13 production inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090170116-A1 | IL-13 Production Inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1852503-A1 | IL-13 PRODUCTION INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7202040-B2 | Method for screening compounds which change the binding properties of a protein with a ligand | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20050154190-A1 | Screening method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1455186-A1 | SCREENING METHOD | Takeda Chemical Industries, Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154190-A1 | Screening method | SLC6A19, SLC1A5, SLC7A1 | P2RY10 3424/4885GPR34 429/4885GPR174 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.